IN THE CLAIMS

Please amend the claims as follows:

1.   (Currently amended) A composition comprising a TNP-470 conjugated to a polymer, wherein the polymer is ~~water soluble~~ a hydroxypropyl(meth)acrylamide-methacrylic acid copolymer and has a molecular weight not greater than 60 kDa.

2.   (Cancelled)

3.   (Original) The composition of claim 1, wherein the polymer has a molecular weight in the range of 15 to 40 kDa.

4.   (Cancelled)

5.   (Original) The composition of claim 1, further comprising a peptide linker between the TNP-470 and the polymer.

6.   (Original) The composition of claim 1, further comprising a targeting ligand.

7.   (Currently amended) The composition of claim 1 [[4]], comprising the structure:


wherein y is in the range of 0.04-20 and x is in the range of 80-99.96.

8.   (Previously presented) A method of treating an angiogenic disease comprising administering a composition of claim 1 to a mammal in need thereof, wherein the

angiogenic disease is a solid tumor, a lymphoma, a leukemia, diabetic retinopathy or macular degeneration.

9.   (Cancelled)

10.   (Currently amended) A method for decreasing neurotoxicity of TNP-470, comprising conjugating the TNP-470 to a polymer, wherein the polymer is ~~water soluble~~ a hydroxypropyl(meth)acrylamide-methacrylic acid copolymer and has a molecular weight not greater than 60 kDa.

11.   (Cancelled)

12.   (Previously presented) The method of claim 10, wherein the polymer has a molecular weight in the range of 15 to 40 kDa.

13.   (Cancelled)

14   (Original) The method of claim 10, further comprising a peptide linker between the antiangiogenic agent and the polymer.

15. (Original) The method of claim 10, comprising the structure:

wherein y is in the range of 0.04-20 and x is in the range of 80-99.96.

16. (Original) The method of claim 15, wherein y is 5-10 and x is 90-95.

17. (Currently amended) An HPMA-TNP-470 conjugate comprising the structure:

Wherein wherein x is 90-95 and y is 5-10.